I undersøgelse 6 var betydeligt sværere allergiske astmapatienter på Xolair i stand til at reducere deres flutikasondosis til ≤500 mikrogram/ dagligt uden forværring af astmakontrol (60, 3%) sammenlignet med placebogruppen (45, 8%, p < 0, 05).
In study 6, significantly more severe allergic asthma patients on Xolair were able to reduce their fluticasone dose to ≤ 500 micrograms/ day without deterioration of asthma control (60.3%) compared to the placebo group (45.8%, p < 0.05).